NCT04317885View on ClinicalTrials.gov

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

December 30, 2023

Conditions
Non-Hodgkin's B-cell Lymphoma
Interventions
BIOLOGICAL

Prizloncabtagene Autoleucel

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

200065

Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER

NCT04317885 - A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Biotech Hunter | Biotech Hunter